BSX

Business Context and Reporting Period

Company: Boston Scientific Corporation (BSX)
Filing Type: Form 10-Q (Quarterly Report)
Reporting Period: Three and six months ended June 30, 2026
Business Overview: Global developer, manufacturer, and marketer of medical devices used in interventional medical specialties, organized into two reportable segments: MedSurg and Cardiovascular.

Key Financial Metrics

Note: Free Cash Flow calculated as Operating Cash Flow less Capital Expenditures ($372M YTD 2026) = $1,450M.

Material Changes vs. Prior Period

• Revenue Growth: Net sales increased 7.5% in Q2 and 9.5% YTD compared to the prior year. Organic growth was 7.0% in Q2 and 8.1% YTD, driven by strong performance in Interventional Cardiology & Vascular Therapies and Electrophysiology.
• Profitability: Operating income rose 44% in Q2 and 31% YTD. Gross margin expanded by 300 basis points in Q2 due to higher sales of high-margin products, tariff recoveries, and reduced inventory charges.
• One-Time Items:
  • Litigation: Recorded $76 million in litigation-related net charges in Q2 2026 (none in Q2 2025), primarily related to product liability and defense costs.
  • Tax Benefit: YTD 2026 included a discrete tax benefit of $384 million related to changes in anticipated future tax rates for capitalized expenses.
  • Restructuring: Net restructuring charges were $8 million in Q2 2026 compared to $83 million in Q2 2025.
• Share Repurchases: Executed a $2.0 billion accelerated share repurchase (ASR) in Q2 2026, settling for approximately 40 million shares.

Guidance, Outlook, and Risks

• Acquisitions:
  • Penumbra: Definitive agreement to acquire Penumbra, Inc. for approximately $14.5 billion. Expected to close in H2 2026 pending FTC clearance (Second Request issued March 2026).
  • Scivita Medical: Agreement to acquire remaining stake for ~$200 million upfront; expected to close Q3 2026.
  • Nalu Medical: Completed acquisition in January 2026 for ~$523 million net cash.
• Restructuring Plan: On July 21, 2026, the Board approved a new global restructuring program (2026 Plan) with estimated pre-tax charges of $700–$800 million, expected to reduce annual pre-tax expenses by ~$500 million upon completion by end of 2029.
• Liquidity & Debt: Entered new $3.0 billion revolving credit facility and $6.0 billion term loan facility (for Penumbra funding) in February 2026. Commercial paper outstanding was $1.689 billion as of June 30, 2026. Leverage ratio is 2.02x, well below the 4.00x covenant maximum.
• Risks:
  • Regulatory: Ongoing FTC review of the Penumbra acquisition.
  • Legal: Significant exposure to product liability litigation (transvaginal mesh, spinal cord stimulators) and patent disputes (University of Texas System case resolved favorably in July 2026).
  • Macro: Exposure to foreign currency fluctuations, geopolitical tensions, and supply chain disruptions.

Investor Verification Checklist

• Penumbra Acquisition Status: Monitor FTC clearance progress and potential delays impacting H2 2026 closing.
• Restructuring Execution: Verify the timing and cash impact of the new $700–$800 million restructuring plan approved in July 2026.
• Litigation Reserves: Review the $282 million legal accrual and potential for additional charges related to spinal cord stimulator and mesh litigation.
• Tax Rate Volatility: Assess the sustainability of the effective tax rate given the $384 million discrete benefit in YTD 2026.
• Debt Capacity: Confirm availability of the $6.0 billion term loan facility for the Penumbra transaction and impact on leverage ratios post-closing.